Compare CRWD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRWD | VRTX |
|---|---|---|
| Founded | 2011 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.2B | 115.7B |
| IPO Year | 2019 | 2006 |
| Metric | CRWD | VRTX |
|---|---|---|
| Price | $390.39 | $476.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 44 | 27 |
| Target Price | ★ $546.37 | $526.79 |
| AVG Volume (30 Days) | ★ 2.9M | 1.4M |
| Earning Date | 03-01-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | N/A | ★ 15.32 |
| Revenue | ★ $3,953,624,000.00 | $2,488,652,000.00 |
| Revenue This Year | $23.94 | $11.10 |
| Revenue Next Year | $22.02 | $10.23 |
| P/E Ratio | ★ N/A | $30.60 |
| Revenue Growth | 29.39 | ★ 46.20 |
| 52 Week Low | $298.14 | $362.50 |
| 52 Week High | $566.90 | $519.68 |
| Indicator | CRWD | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.00 | 52.45 |
| Support Level | $400.02 | $463.00 |
| Resistance Level | $432.85 | $503.88 |
| Average True Range (ATR) | 20.00 | 14.23 |
| MACD | 3.06 | -0.45 |
| Stochastic Oscillator | 77.81 | 35.21 |
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.